TRIAMCINOLONE ACETONIDE

Post-LOE

triamcinolone acetonide

Hikma

ANDAINJECTIONINJECTABLE

Approved

Dec 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TRIAMCINOLONE ACETONIDE (triamcinolone acetonide) by Hikma is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2024.

Drug data last refreshed 21h ago

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (14)

NCT04598542Phase 1Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Started Oct 2020

40 enrolled

Drug-Drug Interaction

NCT03203447Phase 3Terminated

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Started Mar 2018

325 enrolled

Macular EdemaRetinal Vein Occlusion

NCT02980874Phase 3Terminated

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Started Jan 2017

460 enrolled

Macular EdemaRetinal Vein Occlusion

NCT02598869Phase 4Withdrawn

Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema

Started Nov 2015

UveitisCystoid Macular Edema

NCT02303184Phase 2Completed

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Started Jan 2015

46 enrolled

Macular EdemaRetinal Vein Occlusion

Worked on TRIAMCINOLONE ACETONIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.